FMED Stock Overview
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Fresenius Medical Care AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €42.41 |
| 52 Week High | €42.41 |
| 52 Week Low | €33.60 |
| Beta | 0.85 |
| 11 Month Change | 9.66% |
| 3 Month Change | 23.90% |
| 1 Year Change | 18.10% |
| 33 Year Change | -22.97% |
| 5 Year Change | -36.48% |
| Change since IPO | -20.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| FMED | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 2.6% | 0.6% | 2.2% |
| 1Y | 18.1% | -22.6% | 8.0% |
Return vs Industry: FMED exceeded the UK Healthcare industry which returned -22.6% over the past year.
Return vs Market: FMED exceeded the UK Market which returned 8% over the past year.
Price Volatility
| FMED volatility | |
|---|---|
| FMED Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: FMED's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine FMED's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 113,079 | Helen Giza | www.freseniusmedicalcare.com |
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.
Fresenius Medical Care AG Fundamentals Summary
| FMED fundamental statistics | |
|---|---|
| Market cap | €12.40b |
| Earnings (TTM) | €658.94m |
| Revenue (TTM) | €19.24b |
18.8x
P/E Ratio0.6x
P/S RatioIs FMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FMED income statement (TTM) | |
|---|---|
| Revenue | €19.24b |
| Cost of Revenue | €14.40b |
| Gross Profit | €4.84b |
| Other Expenses | €4.18b |
| Earnings | €658.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 2.25 |
| Gross Margin | 25.14% |
| Net Profit Margin | 3.43% |
| Debt/Equity Ratio | 49.4% |
How did FMED perform over the long term?
See historical performance and comparison